Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Virus-specific T-cells for Resistant Viral Infections Post-HSCT
NCT05075837Phase 1Not yet recruiting
- Sponsor
- Istituto Giannina Gaslini
- Start
- Feb 2024
- Primary completion
- Jul 2024
- Modality
- Adoptive Cell Transfer
01
Overview
Phase 1, open-label, single-arm trial of virus-specific T cells in cytomegalovirus infection (CMV), Epstein-Barr virus infection and adenovirus infection, sponsored by Istituto Giannina Gaslini. Primary endpoint: Adverse events. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
virus-specific T cells
03
Conditions
cytomegalovirus infection (CMV)Epstein-Barr virus infectionadenovirus infection
Beyond the preview
Go deeper on NCT05075837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05075837.